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Abstract
Background: The PTEN (Phosphatase and Tensin homolog deleted on chromosome Ten) tumor
suppressor gene is frequently mutated or deleted in a wide variety of solid tumors, and these
cancers are generally more aggressive and difficult to treat than those possessing wild type PTEN.
While PTEN lies upstream of the phosphoinositide-3 kinase signaling pathway, the mechanisms that
mediate its effects on tumor survival remain incompletely understood. Renal cell carcinoma (RCC)
is associated with frequent treatment failures (~90% in metastatic cases), and these tumors
frequently contain PTEN abnormalities.
Results: Using the ACHN cell line containing wild type PTEN, we generated a stable PTEN
knockdown RCC cell line using RNA interference. We then used this PTEN knockdown cell line
to show that PTEN attenuation increases resistance to cisplatin-induced apoptosis, a finding
associated with increased levels of the cyclin kinase inhibitor p21. Elevated levels of p21 result from
stabilization of the protein, and they are dependent on the activities of phosphoinositide-3 kinase
and Akt. More specifically, the accumulation of p21 occurs preferentially in the cytosolic
compartment, which likely contributes to both cell cycle progression and resistance to apoptosis.
Conclusion: Since p21 regulates a decision point between repair and apoptosis after DNA
damage, our data suggest that p21 plays a key role in mechanisms used by PTEN-deficient tumors
to escape chemotherapy. This in turn raises the possibility to use p21 attenuators as chemotherapy
sensitizers, an area under active continuing investigation in our laboratories.
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The PTEN (Phosphatase and Tensin homolog deleted on
chromosome Ten) gene encodes a dual lipid and tyrosine
phosphatase that regulates signaling through the PI3K/
Akt pathway [1], and acts as a tumor suppressor protein
that is frequently mutated or deleted in human cancers.
Studies have shown that mice heterozygous for PTEN
develop spontaneous tumors[2,3], and that conditional
tissue-specific tissue disruption of PTEN leads to tumors
in the affected tissues[4,5]. Through its actions on multi-
ple downstream signaling proteins, including but not lim-
ited to the PI3K/Akt pathway, PTEN has the capacity to
affect a variety of cancer-relevant signaling cascades.
Germline mutations of PTEN occur in 80% of patients
with Cowden syndrome, which is characterized by the
occurrence of multiple non-cancerous hamartomas; in
addition, these patients are at high risk for breast, thyroid,
and endometrial carcinomas, as well as an increased risk
of bladder and renal cell carcinoma (RCC)[6]. Consistent
with these data, PTEN protein and gene expression have
been variously described as reduced[7,8], absent[9],
mutated[10], or deleted [11] in human RCCs; a recent
study demonstrated PTEN loss in 20% of RCCs[12] and
another study quoted an LOH of 27% in kidney can-
cer[13]. Since RCC is a malignancy associated with fre-
quent treatment failures when metastatic, and because
RCC and other tumors lacking PTEN are often resistant to
conventional chemotherapy[14,15], the mechanism by
which PTEN contributes to chemotherapy failure is of
immediate clinical importance and may lead to new ther-
apeutic options for patients with such cancers.
Cell cycle progression, both in normal and cancer cells, is
finely regulated by the interplay between the cyclins, cyc-
lin-dependent kinases (CDKs) and CDK inhibitors
(CKIs), as well as by fluctuation in their levels at different
points of the cell cycle (reviewed in [16]). The earliest
described role of p21 was in cyclin/cdk inhibition[17,18],
but more recent data also has shown that p21 is involved
in positive effects on cyclin/cdk activation[17,19,20]
through its "assembly factor" function[21]. In addition,
p21 has been shown to be anti-apoptotic in many tissues,
including cancer [22,23], and, as such, has been suggested
to be a target for cancer therapy[24]. There are also reports
of a role of p21 in inducing senescence, a mechanism
which seems to protect against malignant transforma-
tion[25]. We have previously shown that p21 is a prog-
nostic marker in clear cell RCC (ccRCC) such that its
elevated levels portend a poorer prognosis in patients who
have metastatic ccRCC at diagnosis[26,27].
While p21 is transcriptionally regulated by p53[28]
(hence its function in DNA damage repair), the mecha-
nisms that regulate the activity of p21 and its post-transla-
tional modification are less clear. A previous report
demonstrated that p21 is phosphorylated by Akt, which
leads to increased p21 stability as well as enhanced cell
survival[29], and another report showed that cytoplasmic
localization of p21 results from HER2/Neu activation of
Akt with subsequent p21 phosphorylation[30]. We have
shown that p21 accumulates in the cytoplasm of actively
growing cells [31] and that forced localization of p21 to
the cytosolic compartment results in increased cell
growth[32] and resistance to apoptosis [33]. Given the
complex relationship between PTEN, phosphoinositide-3
kinase (PI3K), Akt, and p21, which are all signaling pro-
teins involved in cell growth and apoptosis in cancer, we
now address how PTEN deficiency influences p21. In this
study, we demonstrate that, in an RCC cell line that
retains wild type genes for PTEN and p53, knockdown of
PTEN using RNA inhibition increases p21 stability, but
not transcription. This event results in increased cytosolic
localization of this protein, a property which, having been
earlier shown to result in apoptosis resistance and cell
cycle progression, may explain the chemoresistance of
PTEN-deleted tumors.
Results
Rapamycin decreases p21 in response to cisplatin-induced 
DNA damage
Inhibition of mTOR has been shown to decrease p21 in
human non-small cell lung carcinoma cells, and, in fact,
such attenuation of p21 is required for sensitization of
these cells to apoptosis induced by DNA damage [34]. A
clinical trial using the rapamycin analog CCI-779 (an
mTOR inhibitor) showed this compound has antitumor
activity against RCC[35]. We thus hypothesized that both
the results from this trial and the chemotherapy resistance
that is characteristic of PTEN-deficient RCC may be due, at
least in part, to the anti-apoptotic function of p21.
There is no "standard" chemotherapeutic agent in RCC,
since none has been proven unequivocally effective in this
disease [36] which is highly resistant to chemother-
apy[37]. However, for these studies we have utilized the
DNA-damaging agent cisplatin, given the available data
on sensitization of tumor cells to this agent with p21
attenuation by the mTOR inhibitors and other
agents[24,34]. To begin to address the hypothesis that the
chemotherapy resistance of PTEN-deficient RCC may be
due to p21 induction, we asked whether cisplatin
increases p21 in ACHN cells (a PTEN-wt ccRCC cell line)
and whether this increase is antagonized by mTOR inhibi-
tion (which has been shown to have antitumor activity).
When ACHN cells were incubated with cisplatin at con-
centrations of 0.001 and 0.01 μg/ml, p21 levels increased,
presumably in response to DNA damage; yet, this increase
did not occur in cells incubated with rapamycin (Fig. 1).
In addition, when used in combination with cisplatin,Page 2 of 14
(page number not for citation purposes)
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Thus, DNA damage leads to increased levels of p21, and
this increase is prevented by inhibition of mTOR.
Knockdown of PTEN increases steady-state levels of p21 
and causes resistance to DNA-damage induced apoptosis
To determine whether the chemotherapy resistance of
PTEN-altered RCCs may relate to p21, we generated two
PTEN-knockdown ccRCC cell lines using RNA interfer-
ence. We utilized an shRNA construct to stably attenuate
PTEN expression in the PTEN-wt RCC cell line, ACHN
(Fig. 2a). Stable clones of PTEN shRNA (N = 2)-, mutant-
shRNA- (Fig. 2a) and empty vector-transfected (control)
cells were selected and examined for expression of PTEN
and p21. As expected, levels of PTEN were significantly
reduced (by as much as 20-fold) in cells transfected with
PTEN shRNA, but not in those containing pSuper (empty)
vector alone or mutant shRNA (Fig. 2b), indicating that
the attenuation of PTEN was not due to non-specific
effects of introducing shRNA into the cells.
To determine whether PTEN-knockdown cells were asso-
ciated with apoptosis resistance, we incubated these cells
with various concentrations of cisplatin as well as with the
known apoptosis inducer camptothecin. At cisplatin con-
centrations of 0.1 and 1.0 μg/ml, as well as with incuba-
tion of camptothecin at 4 μM, the PTEN-knockdown cells
were resistant to apoptosis measured by total Caspase
activity (Fig. 3). Intriguingly, p21 levels were increased by
~5-fold in the PTEN-knockdown cells (Fig. 4) suggesting
that p21 is involved in the resistance to apoptosis seen
upon loss or inactivation of PTEN; subsequent experi-
ments were performed to ascertain the mechanisms
underlying this effect.
In order to demonstrate universality of the PTEN/p21
relationship, we re-examined a series of naturally occur-
ring canine melanomas on which we had previously
reported expression or tumor suppressor and cell cycle
proteins[38]. Semi-quantitative assessment of p21 and
PTEN using immunohistochemistry showed an inversely
proportional relationship between expression of PTEN
and cytoplasmic localization of p21 (Fig. 5), an indirect
indicator of increased expression (see below). These data
are consistent with what we observed when we knocked
down PTEN in RCC cells in vitro.
Stability of p21 is augmented in PTEN-knockdown cells
In light of previous reports that p21 is phosphorylated by
Akt, a kinase which lies downstream of both PI3K and
PTEN, and that phosphorylation of p21 is associated with
its increased stability [29,30,39], we next asked whether
p21 stability is altered in PTEN-downregulated cells. Since
initial efforts showed no change in p21 mRNA in PTEN
knockdown as compared to PTEN-wt cells (data not
shown), we utilized the protein synthesis inhibitor
cycloheximide (CHX) to assess protein stability. Incuba-
tion of the cells with CHX abolishes translation of new
p21, such that tracking p21 levels over time can be used as
an indicator of its half-life. We incubated ACHN cells with
Cisplatin increases p21 in ACHN cellsFigure 1
Cisplatin increases p21 in ACHN cells. ACHN cells were incubated with cisplatin and/or rapamycin for 24 h at the indi-
cated concentrations and lysates were immunoblotted for p21. β-actin expression was used as a loading control. A represent-
ative experiment is shown of three done.Page 3 of 14
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immunoblotting. Both wild type cells and cells containing
empty pSuper vector as control showed the half-life of
p21 was ~2 h, consistent with previous reports[40,41]
(Fig. 6). However, in PTEN-knockdown cells, p21 degra-
dation was markedly reduced, with minimal change in
p21 protein levels after 2.5 h (Fig. 6).
p21 levels are regulated by the ubiquitin/proteasome
pathway [42], such that a potential mechanism of pro-
longed p21 stability involves inactivation of this system.
Thus, we next examined whether the proteasome system
itself was altered in PTEN-knockdown cells using three
distinct proteasome inhibitors, lactastatin, N-acetyl-L-
leucinyl-L-leucinal-L-norleucinal (LLnL), and MG132. We
found a similar increase in p21 levels after proteasome
inhibition, using each of the inhibitors, in both control
transfectants and PTEN-knockdown cells (Fig. 7), suggest-
ing that the proteasome pathway is intact in both cell
lines. The cells incubated with CHX for 6 h showed mini-
mal p21 due to the relatively short half-life of this protein
(see Fig. 6), a fact which is not altered by the continuing
presence of PTEN shRNA and its effects on PTEN.
Inhibition of PI3K or Akt activation reverts p21 stability in 
PTEN-knockdown cells
While PTEN acts primarily on PI3K through its lipid phos-
phatase activity, it is conceivable that there is a direct effect
of PTEN on p21 that is independent of the PI3K/Akt path-
way, similar to the effects on PTEN on cellular migration
that are mediated partly or exclusively through the C-ter-
minal domains[43]. To investigate this possibility, we
tested p21 stability under conditions where we inhibited
the activity of either PI3K or Akt. First, we confirmed that
loss of PTEN had the expected effects on activation of
PI3K by evaluating Akt phosphorylation at Ser 473 (an
activating event that requires PI3K activity). The levels of
steady state Akt phosphorylation were high both under
conditions of serum-deprivation and serum-stimulation
in PTEN-knockdown cells (Fig. 8, lanes 1 and 2), indicat-
ing that attenuation of PTEN removed its antagonistic
effects on PI3K-mediated Akt activation. Conversely,
serum-deprivation led to a predictable reduction of phos-
pho-Akt in cells transfected with the mutant control
shRNA, yet Akt phosphorylation remained responsive to
serum-stimulation in these cells (Figure 8, lanes 3 and 4),
as is observed in wild type ACHN cells. This provides evi-
dence of specificity, and excludes non-specific effects of
shRNA transfection on PTEN attenuation. We also
observed increased levels of phospho-Mdm2 in PTEN-
knockdown cells (data not shown), which similarly sup-
ports a functional effect of PTEN-knockdown on related
signaling pathways.
Next, we verified that the observed effects of PTEN inhibi-
tion on p21 stability were indeed mediated through
induction of PI3K activity. Incubation of wild type cells
with the selective PI3K antagonists LY-294,002 (10 μM)
or wortmannin (50 nM) for 0.5 to 3 hr completely abol-
ished Akt phosphorylation (Fig. 9). Examination of cells
grown under the previously established conditions of
CHX incubation, and also in the presence of either LY-
294,002 (Fig. 10) or wortmannin (Fig. 11), restored the
kinetics of p21 degradation in PTEN-attenuated cells to
the levels seen in wild type cells and control transfectants;
that is, the half life of this protein (2 – 2.5 h) was no
longer significantly increased in the PTEN-attenuated cells
than it was in the control cells, indicating that the aug-
Attenuation of PTEN expression by pSuper RNAi systemFigure 2
Attenuation of PTEN expression by pSuper RNAi system. a. Illustration of pSuper RNAi construct with mutations (in 
red) in the control shRNA. b. Effect of shRNA on PTEN expression in ACHN cells in two separate experiments.Page 4 of 14
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mediated through PI3K.
There is evidence to suggest that enhanced stability of p21
is caused by phosphorylation of p21 on Ser146 by
Akt[29]. To determine if activated Akt was required for the
stabilization of p21 upon PTEN attenuation, we utilized
PIA5, one of a new class of phosphatidylinositol ether
lipid analogues that prevent Akt activation and can selec-
tively kill lung and breast cancer cells with elevated Akt
activity[44]. When cells were incubated with PIA5 (10
μM) for 30 min prior to addition of CHX, we found that,
as was seen with the PI3K inhibitors, the enhanced stabil-
ity of p21 was abrogated and the half-life of the protein
reverted to that seen in wild-type cells (Fig. 12). Thus,
PTEN augments p21 stability via two downstream ele-
ments of the PI3K growth and survival signaling pathway,
PI3K and Akt.
Cytosolic localization of p21 is augmented in PTEN-
downregulated cells
Subcellular localization of p21 is important in dictating
its effect on cell growth and apoptosis, such that cytosolic
p21 has been shown to result in activation of anti-apop-
totic [33] and proliferative [30,32] machinery, resulting in
more aggressive tumor behavior and a poorer patient
prognosis[26,45,46]. We utilized immunofluorescence
and immunohistochemistry techniques to assess subcel-
lular distribution of p21 in PTEN-knockdown cells.
Results were similar using both methods; i.e., p21 levels
were substantially increased in the PTEN-knockdown cells
as compared to control transfectants (Fig. 13a). Moreover,
cytosolic localization of p21 also was increased in PTEN-
knockdown cells (Fig. 12a).
To confirm this finding, we performed subcellular locali-
zation of PTEN-knockdown and mutant shRNA control
ACHN cells to determine whether p21 is directed more to
the cytosol as a result of PTEN attenuation. In agreement
PTEN-knockdown reduces sensitivity to cisplatin-induced apoptosisFigure 3
PTEN-knockdown reduces sensitivity to cisplatin-induced apoptosis. ACHN cells stably transfected with PTEN-
shRNA (black bars) or pSuper empty vector control (gray bars) were incubated with the indicated concentrations of cisplatin 
for 24 h. Caspase-3 activity was measured as an indicator of apoptosis as described in Materials and Methods.Page 5 of 14
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ratio of p21 in the cytosol as compared to the nucleus was
markedly enhanced in PTEN-KD cells (Fig. 13b). Whether
these findings are due to a generalized increase in cellular
p21 with a stoichiometric redistribution of a proportion
of the total p21 from the nucleus to the cytosol, or to a
specific augmentation of cytosolic p21 through a separate
signaling mechanism (such as alteration of the nuclear
localization sequence), remains to be determined. How-
ever, augmentation of total p21 as well as specific
increases in cytosolic p21 in PTEN-deficient cells may be
an important mechanism through which PTEN-altered
tumors acquire resistance to chemotherapy[24].
Discussion
Many malignancies, including kidney cancer, are charac-
terized by resistance to DNA-damaging chemotherapy.
While the mechanisms of this effect remain incompletely
understood, they appear to relate to activation of survival
pathways that occur in the setting of DNA damage repair.
For example, exposure to ionizing radiation causes DNA
strand breaks leading to increases in p53, which in turn
activates either the cell death (apoptosis) program, or
alternatively, genes involved in cell cycle arrest and subse-
quent DNA repair (reviewed in [24]). Thus, tumors har-
boring p53 mutations (~50% of all human malignancies),
fail to apoptose or growth arrest after DNA dam-
age[47,48] and may thus escape death upon exposure to
chemotherapeutic agents; this can lead to chemotherapy
failure. The cyclin kinase inhibitor p21 is induced by p53
in situations of DNA damage, and it likely plays a role in
the decision pathways leading to apoptosis or DNA repair
[24]; for this reason, not only has p21 been proposed as a
target for chemotherapy sensitization, but also, the mech-
anisms by which p21 becomes activated have attracted
considerable interest in the study of chemotherapy-resist-
ant cancers.
p21 was initially characterized based on its function as an
inhibitor of G1 cyclin kinases [17,18], but after the discov-
ery that p21 possesses pro-proliferative[32] as well as anti-
apoptotic [33] effects, research on this protein expanded
to include to its roles in cancer progression and chemo-
therapy sensitivity. A putative relationship of p21 to PTEN
was proposed after reports emerged that p21 is phospho-
rylated and stabilized by Akt[29,39]. Our present findings
reported here, that PTEN deficiency augments p21 stabil-
ity and alters its subcellular localization so that it is situ-
ated more in the cytosolic compartment, may explain at
least part of the observed chemotherapy resistance that is
observed in PTEN-deficient tumor cell lines as well as in
tumors derived from PTEN-knockout mice[49].
Other investigators have demonstrated a tissue-specific
relationship between PTEN and p21. Using a Cre-Lox
model of tissue-specific PTEN-deficiency, Yoo et al
detected higher levels of p21 protein and transcripts in
PTEN-deficient bladder tissue (but not prostate), a finding
which they interpreted as a potential bladder-specific
tumor suppression mechanism [50]. Another group
showed a similar phenomenon in PTEN-deficient prostate
tissue, which they interpreted as confirming the activation
of a p21-related senescence pathway[25]. However, ours
is the first study to report increased p21 levels and altered
subcellular compartment localization in PTEN-knock-
down cells, and to begin to elucidate a mechanism for this
finding.
Our use of a kidney cancer cell line for these studies was
prompted by the facts that (i) kidney cancer is exquisitely
chemotherapy-resistant such that 5-year survival for the
metastatic form of the disease is less than 10% [36], and
(ii) decreased PTEN expression is frequently seen in this
disease[8,9]. In an earlier study, we found elevated levels
of cytoplasmic p21 expression at time of surgery were
associated with a worse prognosis in patients with meta-
p21 is increased in PTEN-knockdown cellsFigure 4
p21 is increased in PTEN-knockdown cells. ACHN 
cells stably transfected with PTEN-shRNA or empty vector 
control were immunoblotted with PTEN, p21, and β-actin. 
Quantification of p21 and PTEN bands was determined by 
densitometry, normalized to β-actin expression, and 
expressed as fold-change p21/PTEN.Page 6 of 14
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study; assessment of PTEN and p21 status in a small set of
ccRCC (N = 9) from the University of Colorado Hospital
archives showed loss of PTEN and elevated levels of p21
staining in every tumor, as compared to unaffected kidney
samples from age and sex matched controls (R. Weiss, J.
Modiano, and K. Shroyer, unpublished observations).
Akt regulates the balance of apoptosis and cell survival by
phosphorylating proteins crucial in apoptotic and anti-
apoptotic mechanisms. Based on the fact that altered
PTEN expression is often observed in RCC, deregulated
Akt activation is likely one of the underlying mechanisms
of RCC tumorigenesis. Use of the Akt inhibitor of the
phosphatidylinositol ether lipid analogue class that we
utilized in this study has been shown to cause apoptosis
in various RCC lines which are characterized by elevated
Akt activation [8]. Among a variety of downstream targets
of Akt, phosphorylation of Bad, an important pro-apop-
totic protein, was prominently decreased when treated
with the Akt inhibitor, possibly due to decreased Akt activ-
ity. In addition, expression of Bcl-XL, an anti-apoptotic
protein, was decreased resulting in increased cell death.
Consistent with these findings, our data suggest that phar-
maceutical approaches to target Akt inhibition may be
useful in designing more efficient therapeutic regimens
for ccRCC.
The most recognized and universal response of a cell to
DNA damage is activation of p53 transcription, followed
by p53-mediated transcriptional activation. p53, the
"guardian of the genome" is responsible for apoptosis of
cells which cannot be repaired, and some of these bio-
chemical events are mediated by p21[24]. However, it has
been described that PTEN may protect p53 from Mdm-2-
mediated degradation[51], so it is possible that the
observed increase in p21 levels is mediated via p53 or
Mdm-2, or through a p53-independent mechanism.
The clinical relevance of our findings is supported by
recent data indicating that p21 is involved in the mecha-
nism of action of mTOR inhibitors. Beuvink et al showed
that the mTOR inhibitor RAD001 sensitizes cells to DNA
damage-induced apoptosis through inhibition of p21
translation[34]. Our data suggests an explanation for the
anti-tumor activity of mTOR inhibition in a clinical trial
of RCC[35], especially in those RCCs with PTEN altera-
tions, and these data support further trials of mTOR inhib-
itors in RCC and other HIF-activated cancers.
One possible means to sensitize cancer cells to DNA dam-
age induced apoptosis would be to attenuate p21 prior to
application of a DNA damaging agent in order to direct
DNA damaged cells into the apoptotic (rather than the
repair) pathway[23,24]. Our reported successful use of
phosphorothioated antisense p21 oligonucleotides in
several cell lines, including renal mesangial cells
[21,23,52,53], could easily be extended to kidney disease
in vivo, given the high transport of such oligonucleotides
to kidney tubular epithelial cells when systemically
administered[54]. Experiments to test this possibility
using both tissue culture and an animal model of RCC are
currently underway in our laboratory.
Conclusion
In this study, we have found that knockdown of the com-
monly altered tumor suppressor gene PTEN results in
increased stability and cytosolic localization of the pleio-
tropic cell cycle protein p21, both properties being histor-
ically associated with resistance to apoptosis. Whether this
is a mechanism by which tumors escape chemotherapeu-
tic death is a topic of active investigation in our laborato-
ries; however, our findings suggest the use of novel p21-
attenuating methods in combination with conventional
chemotherapy in the treatment of chemotherapy-resistant
kidney and other cancers.
Inverse relationship between expression of PTEN and cyto-plasmic local zation of p21 i canin  melanomaFigur 5
Inverse relationship between expression of PTEN 
and cytoplasmic localization of p21 in canine 
melanoma. A series of naturally occurring canine melano-
mas on which we previously reported expression of PTEN 
and p21 (see text) was re-examined to determine if there 
was a consistent relationship between expression of these 
proteins. Data were evaluated from tumors that had easily 
detectable PTEN staining in >30% of cells (1+, N = 9), weak 
expression of PTEN (required high magnification for confir-
mation) in >30% of cells (+/-, N = 9), or no expression of 
PTEN (-, N = 5). Each tumor was then examined for p21 
intensity and subcellular localization. Data represent the % of 
samples that showed cytoplasmic p21 for each group. The 
numbers over each bar represent the sample size for each 
group; *p < 0.03 compared to PTEN(-).Page 7 of 14
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Chemicals and reagents
The PI3K inhibitors LY-294,002 hydrochloride and wort-
mannin, and the proteasome inhibitors, N-acetyl-L-leuci-
nyl-L-leucinal-L-norleucinal (LLnL), lactacystin and
MG132, were purchased from Sigma-Aldrich (St. Louis,
MO). The Akt inhibitor PIA5 was kindly provided by Dr.
Phillip Dennis (Medical Oncology Branch, NCI). Anti-
Akt, anti-phospho-Akt (Ser473), anti-mono-methyl His-
tone H3, anti-phospho-MDM2 (Ser 166), and anti-PTEN
antibodies were purchased from Cell Signaling Technol-
ogy (Danvers, MA). Anti-p21 antibody was purchased
The stability of p21 is increased by PTEN-knockdownFigure 6
The stability of p21 is increased by PTEN-knockdown. a. Wild type ACHN cells as well as those stablytransfected with 
PTEN-shRNA or empty vector control were incubated with cycloheximide (CHX; 20 μg/ml) for the times indicated and immu-
noblotted with antibodies against p21 and β-actin. b. Graphical representation of the data from densitometric quantification of 
p21 and β-actin reported as ratio of p21/β-actin and normalized to the "0 CHX control" for each lane. A representative exper-
iment of four done is shown.
PTEN knockdown does not alter proteasome-dependent degradationFigure 7
PTEN knockdown does not alter proteasome-dependent degradation. Cells stably transfected with PTEN-shRNA or 
empty vector were treated with three different proteasome inhibitors (lactastatin, 20 mM; LLnL, 50 mM; MG132, 1 mM) or 
cycloheximide (CHX; 20 μg/ml) for 6 h, followed by immunoblotting for p21. A representative experiment is shown of three 
done.Page 8 of 14
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Anti-GAPDH antibody was from Chemicon-Millipore
(Temecula, CA). Anti-phospho-threonine antibody was
from Abcam (Cambridge, MA); and phospho-serine
detection kit containing four different anti-phospho-ser-
ine antibodies, was from Calbiochem (San Diego, CA).
Design of vectors for RNA inhibition
We used the pSuper platform (OligoEngine, Seattle, WA)
to clone PTEN short hairpin RNA molecules (shRNAs) as
described[55]. Small inhibitory RNA sequences were
designed using a program similar to OligoEngine and
Ambion (Austin, TX) online tools. Two sites that were
common to both programs were selected, corresponding
to positions 1,159 – 1,181 (AAGGCGTATACAG
GAACAATATT) and 1,469 – 1,491 (AAGGCACAAGAG-
GCCCTAGATTT) from the human PTEN mRNA (Gen-
bank accession # NM000314), where the ATG start site is
at position 1,032. The oligonucleotides were cloned into
the BglII/HindIII sites of the pSuper-puro vector as
described [55]. Specificity controls included the empty
vector and a double base pair mutant for the 1,469 –
1,491 PTEN shRNA sequence (Fig. 1), where the resulting
oligonucleotide did not show any positive matches for
any mammalian sequence using basic blast (NCBI,
National Library of Medicine, NIH). Stable cell lines inte-
grating PTEN shRNA, mutant PTEN control, or empty
pSuper-puro vector were selected in puromycin contain-
ing media.
Cells and cell lines
ACHN human RCC cells (CRL-1161) were obtained from
ATCC (Manassas, VA) and maintained in MEM 1X media
supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, and 1 mM sodium pyruvate. For transfections,
1 × 106 cells were placed in a sterile cuvette with 4 μg of
the corresponding pSuper vector + 1 μg of pEGFP-C vector
(BD-Clontech, Mountain View, CA), and transfected
using the AMAXA Nucleofector (Amaxa, Gaithersburg,
MD) in solution V, program T20 following the manufac-
turer's instructions for transfection of adherent cells.
Transfection efficiency was monitored microscopically
based on the number of cells showing green fluorescence.
Selection of stable cell lines was accomplished by adding
2.5 μg/ml puromycin to cells 24 hr after transfection. After
5 days, surviving cells were transferred to media contain-
Akt phosphorylation is increased in PTEN-knockdown cellsFigure 8
Akt phosphorylation is increased in PTEN-knockdown cells. Subconfluent ACHN cells stably transfected with PTEN 
or mutant control shRNA were transferred to serum-deficient media (0.5% FBS). After 18 hr, fresh serum-deficient media 
(0.5% serum, "-") or serum-replete media (10% serum, "+") was added for 30 minutes. Cell lysates were immunoblotted with 
antibodies against phosphorylated and total Akt. Lysates from 3T3 murine fibroblasts were used as controls. Densitometry of 
p-Akt is normalized to Akt.Page 9 of 14
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that formulation throughout the duration of experiments.
Retention of the transfected plasmids was routinely mon-
itored by assessing green fluorescence in cells under selec-
tion, and by repeated assessment of PTEN levels using
immunoblotting.
Western blotting
Cells were solubilized in lysis buffer (50 mM HEPES, 1%
Triton X-100, 10 mM Na Pyrophosphate, 100 mM Na Flu-
oride, 4 mM EDTA) and equal protein quantities were
electrophoresed and immunoblotted as previously
described [21]. The membranes were blocked in 5–10%
non-fat dry milk or 1% BSA (for modification-state anti-
bodies) for 1 h at room temperature, and probed with
appropriate antibodies. Membranes were then probed
with HRP-tagged anti-mouse or anti-rabbit IgG antibodies
(Bio-Rad; Amersham) diluted 1:5,000 – 1:15,000 in 2.5–
5% non-fat dry milk for 1 h at room temperature. Chemi-
Akt phosphorylation is reduced by PI3K inhibitionFigure 9
Akt phosphorylation is reduced by PI3K inhibition. Wild type ACHN cells were incubated with (a) LY-294,002 (10 μM) 
or (b) wortmannin (50 nM) for the times indicated and immunoblotted with antibodies against Akt, phospho-Akt, or β-actin. A 
representative experiments is shown of three done.
Stabilization of p21 in PTEN-knockdown cells iseabrogated by PI3K inhibition with LY-294,002Figure 10
Stabilization of p21 in PTEN-knockdown cells iseabrogated by PI3K inhibition with LY-294,002. a. Wild type 
ACHN cells as well as those stably transfected with PTEN-shRNA or empty vector were incubated with LY-294,002 (10 μM) 
for the times indicated in the presence of cycloheximide (CHX; 20 μg/ml) for the times indicated, and cell lysate was immuno-
blotted with antibodies against p21 or β-actin. b. A graphical representation of the data using densitometry of p21 and actin 
bands is reported as ratio of p21/β-actin and is normalized to the "0 CHX control" for each lane. A representative experiment 
is shown of three done.Page 10 of 14
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Amersham Biosciences).
Immunohistochemistry
Data previously reported in reference[38] were re-evalu-
ated to determine the universality of the relationship
between expression and localization of PTEN and p21.
Stabilization of p21 in PTEN-knockdown cells is abrogated by PI3K inhibition with wortmanninFigure 11
Stabilization of p21 in PTEN-knockdown cells is abrogated by PI3K inhibition with wortmannin. a. Wild type 
ACHN cells as well as those stably transfected with PTEN-shRNA or empty vector were incubated with wortmannin (50 nM) 
for the times indicated in the presence of cycloheximide (CHX; 20 μg/ml) for the times indicated, and cell lysates were immu-
noblotted with antibodies to p21 and β-actin. b. A graphical representation of the data using densitometry of p21 and actin 
bands is reported as ratio of p21/β-actin and is normalized to the "0 CHX control" for each lane. A representative experiment 
is shown of three done.
Stabilization of p21 in PTEN-knockdown cells is abrogated by Akt inhibitionFigure 12
Stabilization of p21 in PTEN-knockdown cells is abrogated by Akt inhibition. a. Wild type ACHN cells as well as 
those stably transfected with PTEN-shPNA or empty vector were incubated with the phosphatidylinositol ether lipid analog 
PIA5 (10 μM), which prevents Akt activation, for the times indicated in the presence or absence of cycloheximide (CHX;20 μg/
ml), and cell lysate was immunoblotted with antibodies against p21 and β-actin. b. A graphical representation of the data using 
densitometry of p21 and β-actin bands is reported as ratio of p21/actin and is normalized to the "0 CHX control" foreach lane. 
A representative experiment is shown of three done.Page 11 of 14
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identified and 5 μm serial sections from paraffin-embed-
ded blocks were mounted onto positively charged slides
(Probe-on, Fisher Scientific, Pittsburgh, PA). Immunos-
taining was performed using a modified streptavidin-
biotin complex method. Antigen retrieval was done by
microwave heating for 6 minutes in a buffer of 0.1 M
sodium citrate (pH 6). Samples were graded for intensity
and percentage of positive cells, as well as for subcellular
location of the relevant stain. Samples were considered
negative when no staining was seen above that seen in
negative controls. Staining that was fine, diffuse, and not
always visible at low magnification (40–100-X), but was
readily detectable in >30% of cells at high magnification
(4,000-X) was considered weak. Staining that was promi-
nent enough to be seen at low magnification in >30% of
cells (and was verifiable as specific staining at high mag-
nification) was considered moderate to strong. Samples
were only considered positive when expression of these
proteins was clearly detectable in melanocytic tumor cells
(versus supporting stroma or inflammatory cells) based
on the expression of S100a protein, Melan A, or neuron-
specific enolase in serial sections from the tumors.
Protein stability assays
Approximately 2.5 × 105 cells were grown on 6-well tissue
culture dishes in media containing 10% fetal bovine
serum. Cells were treated with 20 μg/ml cycloheximide
(Sigma-Aldrich) at 30 min interval up to a maximum of
2.5 h. Cells were collected and analyzed by immunoblot-
ting.
Immunofluorescence microscopy
Cells were grown on Lab-Tek multi-chamber slides (Nalge
Nunc International, Rochester; NY, USA) and fixed in cold
methanol for 10 min at -20°C. Fixed cells were rehydrated
with PBS and blocked with 10% goat serum (Jackson
ImmunoResearch Laboratories, Inc.) for 1 h at room tem-
perature. Cells were incubated with anti-p21 antibody
(1:50) for 30 min at room temperature, followed by a sec-
ondary goat anti-mouse IgG antibody (1:1000) conju-
gated to Alexa-Fluor 594 (Molecular Probes) for 30 min at
room temperature. DAPI (0.1 μg/ml, 5 min at room tem-
perature) was used for nuclear counterstaining. The LSM 5
Pascal confocal laser scanning microscope was used for
imaging (Carl Zeiss; Thornwood, NY, USA).
Caspase assay
The CaspACE assay kit (Promega, Madison, WI) was used
to measure caspase-3 activity per the manufacturer's
instructions. Briefly, 106 cells per 10 cm dish were treated
as described in the text. Positive control cells were treated
with 4 μM camptothecin. The cells were harvested,
washed, and equal protein quantities were incubated with
PTEN attenuation enhances p21 expression and cytosolic localizationFigure 13
PTEN attenuation enhances p21 expression and cytosolic localization. a. ACHN cells stably transfected with PTEN-
shRNA or empty vector were immunostained with anti-p21 antibody combined with Alexa Fluor® 594-conjugated secondary 
antibody for detection under UV microscopy. DAPI was used to demarcate nuclei, and EGFP (expressed by the plasmid) was 
used as a transfection control. b. Cells were fractionated for immunoblotting, with antibodies against mono methyl Histone 
H3-Lys4 and GAPDH used as nuclear and cytosolic controls, and p21 levels were quantified using densitometry. The ratio of 
cytosolic/nuclear p21 is shown graphically; the error bars indicate intra-experimental variation (standard deviation) from two 
replicates.Page 12 of 14
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Buffer. The plates were covered with parafilm and incu-
bated at 37°C overnight. Color development was meas-
ured at 405 nm.
Subcellular fractionation
Cells were grown in 100 cm dishes to 95% confluency fol-
lowed by separation into nuclear and cytosolic fractions
using the Panomics Nucelar extraction kit (Panomics, Fre-
mont, CA) according to the manufacturer's instructions.
Briefly, cells were washed with PBS twice and lysed in a
buffer containing 100 mM HEPES, pH 7.9, 100 mM KCl,
and 100 mM EDTA on ice for 10 minutes. Lysates were
centrifuged at 15,000 × g for 3 min at 4°C to obtain
cytosolic extracts. Soluble nuclear extracts were obtained
by vortexing nuclear pellets in a buffer containing 100
mM HEPES, pH 7.9, 2 M NaCl, 5 mM EDTA, 50% glyc-
erol, protease inhibitor cocktail and 100 mM DTT for 10
sec and then centrifuged at 15,000 × g for 5 min at 4°C.
Protein concentrations in each fraction were determined
using the BioRad protein assay. Relative enrichment of the
cytosolic and nuclear fractions, respectively, were deter-
mined by immunoblotting with antibodies against
GAPDH and Mono-Methyl Histone H3.
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